Premium Technology

Showing 4355 articles
Business

Avnet's Soaring Stock: A Valuation Puzzle After a Stellar Run

Avnet's shares have surged over 28% this year, riding the wave of tech hardware demand cycles. But as the stock hovers around $63, a critical question emerges: is the rally justified by fundamentals, or has momentum outpaced value? A deep dive into the numbers reveals a starkly divided picture.

Business

CytomX Therapeutics Surges on Promising Early Colorectal Cancer Data, Analysts Bullish on Probody Platform

Shares of CytomX Therapeutics (CTMX) jumped over 14% this week after early-stage clinical data for its lead Probody candidate, varsetatug maseatecan, in metastatic colorectal cancer drew positive reactions from Wall Street. The move highlights growing confidence in the company's conditionally activated antibody platform, designed to target tumors more precisely while sparing healthy tissue.

Business

Arcellx Stock: A Tale of Two Valuations Amid Biotech Volatility

Arcellx (ACLX) shares are caught in a tug-of-war between conflicting valuation signals. While a sky-high price-to-book ratio suggests the stock is richly valued, a discounted cash flow model implies massive upside potential. We examine the data behind the biotech's recent price swings and what investors are really betting on.